Canada may have tempered an argument against the Trump administration’s international reference pricing plan when it removed the United States from the list of countries it references when setting drug prices. The argument is that HHS’ proposed International Pricing Index ties Medicare Part B drug prices to prices in countries that, in turn, reference drug prices in the United States, but it seems Canada was one of only two countries on the IPI reference-country list to reference U.S. drug prices...